ORIC Pharmaceuticals, Inc.

NASDAQ:ORIC

9 (USD) • At close October 29, 2024
Bedrijfsnaam ORIC Pharmaceuticals, Inc.
Symbool ORIC
Munteenheid USD
Prijs 9
Beurswaarde 634,882,500
Dividendpercentage 0%
52-weken bereik 5.85 - 16.65
Industrie Biotechnology
Sector Healthcare
CEO Dr. Jacob M. Chacko M.B.A., M.D.
Website https://www.oricpharma.com

An error occurred while fetching data.

Over ORIC Pharmaceuticals, Inc.

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the

Vergelijkbare Aandelen

Apyx Medical Corporation logo

Apyx Medical Corporation

APYX

1.25 USD

Gritstone bio, Inc. logo

Gritstone bio, Inc.

GRTS

0.032 USD

CorMedix Inc. logo

CorMedix Inc.

CRMD

12.97 USD

Gamida Cell Ltd. logo

Gamida Cell Ltd.

GMDA

0.033 USD

Graphite Bio, Inc. logo

Graphite Bio, Inc.

GRPH

3.18 USD

Pieris Pharmaceuticals, Inc. logo

Pieris Pharmaceuticals, Inc.

PIRS

17 USD

Genenta Science S.p.A. logo

Genenta Science S.p.A.

GNTA

5.35 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)